Charles C J Carpenter Professor of Medicine

Dr. Carpenter is Director of the Lifespan/Tufts/Brown Center for AIDS Research. He has served as Chair of the Treatment Subcommittee of the Congressionally mandated NAS/IOM Committee to evaluate the President's Emergency Plan for HIV/AIDS Relief (PEPFAR).

Dr. Carpenter has been involved in the care of persons living with HIV since 1982. He served as the site Director of the longitudinal CDC-supported HIV Epidemiology Research Study (HERS) from 1992-1999, and then as Principal Investigator of the CDC-supported SUN Study of the Natural History of HIV/AIDS in the era of effective antiretroviral therapy from 2004-2011.

Dr. Carpenter has been a member of the Executive Committee of the Brown University Fogarty AITRP Program since its inception, has participated in the training of Fogarty fellows from each of the participating sites, and is currently involved in on-going research in Chennai, India.

Brown Affiliations

scholarly work

Carpenter CCJ. Universal access to antiretroviral therapy: When, not if. Editorial Clin Inf Dis 42:260-1, 2006.

Tashima KT, Carpenter CCJ. Fusion inhibition – A major but costly step forward in HIV-1 treatment. N Engl J Med 348:2249-50, 2003.

Carpenter CCJ, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, et. al. Antiretroviral therapy in adults. Updated recommendations of the International AIDS Society-USA panel. JAMA 283(3):381-90, 2000.

Feinberg MB, Carpenter C, Fauci AS, Stanley SK, Cohen O, Bartlett JG, Kaplan JE, Abrutyn E. Report of the NIH panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Ann Int Med 128:12(2):1057-1100, 1998.

Carpenter CCJ, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, et. al. Antiretroviral therapy for HIV infection in 1996: Recommendations of an international panel. JAMA 276:146-54, 1996.

Carpenter CCJ, Mayer KH, Stein MD, Leibman BD, Fisher A, Fiore TC. HIV infection in North American women: experience with 200 cases and a review of the literature. Medicine 70(5):307?325, 1991.

Carpenter CCJ. Today's Challenge: Rigorous Biomedical Science, Globally Applied. Presidential Address, Association of American Physicians. Trans Assoc Am Phys 101:cxx-cxxiii, 1988.

Carpenter CCJ. Oral rehydration: is it good enough for the developed world? Editorial. New Engl J Med 306:1103, 1982.

Guerrant RL, Ganguly V, Casper AGT, Moore EJ, Pierce NF, Carpenter CCJ. Effect of Escherichia Coli on fluid transport across canine small bowel. J Clin Invest 52:1707, 1973.

Pierce NF, Greenough WB, Carpenter CCJ. Vibrio cholerae enterotoxin and its mode of action. Bact Rev 25:1, 1971.

Carpenter CCJ, Greenough WB. Response of the canine duodenum to intraluminal challenge with cholera exotoxin. J Clin Invest 47:2600, 1968.

Carpenter CCJ, Sack RB, Feeley JC, Steenburg, RW: Site and characteristics of electrolyte loss and effect of intraluminal glucose in experimental canine cholera. J Clin Invest 47:1210, 1968.

Carpenter CCJ, Solomon N, Silverberg SG, Bledsoe T, Northcutt RC, Klinenberg JR, Bennett IL, Harvey AM. Schmidt's syndrome (thyroid and adrenal insufficiency): a review of the literature and a report of 15 new cases including 10 instances of coexistent diabetes mellitus. Medicine 43:153, 1964.

Ayers CR, Davis JO, Lieberman F, Carpenter CCJ, Berman M. Effects of chronic hepatic venous congestion on metabolism of aldosterone. J Clin Invest 41:884, 1962.

Carpenter CCJ, Davis JO, Ayers CR. Relation of renin, angiotensin II, and experimental renal hypertension to aldosterone secretion. J Clin Invest 40:2026, 1961.

Davis JO, Ayers CR, Carpenter CCJ. Renal origin of an aldosterone stimulating hormone in dogs with thoracic caval constriction and in sodium-depleted dogs. J Clin Invest 40:1466, 1961.

Carpenter CCJ, Davis JO, and Ayers CR. Concerning the role of arterial baroreceptors in the control of aldosterone secretion. J Clin Invest 40:160, 1961.

Davis JO, Carpenter CCJ, Ayers CR, Holman JR, and Bahn RC. Evidence for secretion of an aldosterone-stimulating hormone by the kidney. J Clin Invest 40:684, 1961.

Carpenter CCJ, Davis JO, Holman JE, Ayers CR, and Bahn RC. Studies on the response of the transplanted kidney and the transplanted adrenal gland to thoracic inferior vena caval constriction. J Clin Invest 40:196, 1961.

research overview

Charles Carpenter's research over the past decade has been directed toward two main areas, the optimal treatment of HIV infection in North American women and therapeutic strategies that are effective in the developing world.

research statement

Dr. Carpenter and his colleagues, Susan Cu-Uvin and Timothy Flanigan, have developed the Miriam Immunology Center, which now provides medical care for over 90% of the women in Rhode Island with HIV infection. In this setting they have, in collaboration with colleagues at three other academic medical centers, completed the HIV Epidemiology Research Study (HERS), which has defined the clinical course and response to effective antiretroviral therapy, over a 7-year period, in a cohort of over 1,000 North American women.

Dr. Carpenter has also contributed to studies in Chennai, India which have helped to define practical antiretroviral regimens that can be utilized on a large scale in developing countries with a very high prevalence of HIV infection. These studies are continuing at the present time.

He has been Director of the National Institutes of Health (NIH)-supported Lifespan/Tufts/Brown Center for AIDS Research since 1998. He has served as a member of the NIH/NIAID/DAIDS, HIV/AIDS Clinical Trials Networks Strategic Working Group since 2008, and currently serves as the U.S. Chair of the U.S.-India Joint Working Group on HIV/AIDS.

funded research

P30 AI-42853-05, Carpenter C (PI) 9/01/12-6/30/17 40%
National Institutes of Health $8,351,725
Lifespan/Tufts/Brown Center for AIDS Research

This is a multi-institutional Center for AIDS Research, for which the goals are: 1) to stimulate translational AIDS research with women, minorities, and other underrepresented groups, 2) to encourage multidisciplinary research on clinical issues related to new therapies and the accompanying extended survival of HIV-seropositive patients, and 3) to support and mentor basic biomedical scientists who are initiating HIV/AIDS research.

N-00403 Carpenter C (PI) 9/13/02-9/12/12 12%
Centers for Disease Control & Prevention $2,775,824
(SUN) Study of the Unnatural History of HIV

The major goals of this project are to study the many manifestations, morbidities, and mortalities of human immunodeficiency virus (HIV), in women and men, in the post highly active antiretroviral therapy (HAART) era (since 1996) and to incorporate HIV prevention activities into HIV medical care.